Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement

Circulation

Volumn 113, Issue 4, 2006, Pages 564-569

  Meurin, Philippe ^a   Tabet, Jean Yves ^a   Weber, Hélène ^a   Renaud, Nathalie ^a   Driss, Ahmed Ben ^a  

^a Les Grands Prés ^*  (France)

Author keywords

Heparin; Prosthesis; Valves

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; AGING; ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TAMPONADE; HEART VALVE PROSTHESIS; HEMATOMA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REPLACEMENT; PERICARDIOTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SURGICAL PATIENT; THROMBOEMBOLISM; TREATMENT OUTCOME; CLINICAL TRIAL; MIDDLE AGED; POSTOPERATIVE COMPLICATION; THROMBOSIS; VALVULAR HEART DISEASE;

AGED; ANTICOAGULANTS; FEMALE; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 33644854461     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.575571     Document Type: Article

References (24)

1. Weitz JL. Low molecular weight heparins. N Engl J Med. 1997;337:688-698.
2. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, Bogaerts K, Danays T, Lindahl B, Makijarvi M, Verheugt F, Van de Werf F. Efficacy and safety of tenecteplase in combination with the low molecular weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)3- plus randomized trial in acute myocardial infarction. Circulation. 2003;108:135-42.
3. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non ST segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89-96.
4. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA; ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of non valvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004;109: 997-1003.
5. Montalescot G, Polle V, Collet JP, Leprince P, Bellanger A, Gandjbakhch I, Thomas D. Low molecular weight heparin after mechanical heart valve replacement. Circulation. 2001;101:1083-1086.
6. Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AG, Bates SM, Desjardins L, Douketis J, Kahn SR, Solymoss S, Wells PS. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110:1658-1663.
7. Douketis JD, Johnson JA, Turpie AG. Low molecular weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164:1319-1326.
8. Fanikos J, Tsilimingras K, Kucher N, Rosen AB, Hieblinger MD, Goldhaber SZ. Comparison of efficacy, safety, and cost of low molecular weight heparin with continuous infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am J Cardiol. 2004;93:247-250.
9. Laffort P, Roudaut R, Roques X, Lafitte S, Deville C, Bonnet J, Baudet E. Early and long term (one year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St Jude medical prosthesis: a clinical and transesophageal echocardiographic study. J Am Coll Cardiol. 2000;35:739-746.
10. Ionescu A, Payne N, Fraser AG, Giddings J, Grunkemeier GL, Butchart EG. Incidence of embolism and paravalvular leak after St Jude Silzone valve implantation: experience from the Cardiff Embolic Risk Factor Study. Heart. 2003;89:1055-1061.
11. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, Pauker SG Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):457S-482S.
12. Bonow RO, Carabello B, de Leon AC Jr, Edmunds LH Jr, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Gibbons RJ, Russell RO, Ryan TJ, Smith SC Jr. Guidelines for the management of patients with valvular heart disease: executive summary: a report of the Am College of Cardiology/Am Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation. 1998;98:1949-1984.
13. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004;110:392-398.
14. The TIMI 11A Trial Investigators. Dose ranging trial of enoxaparin for unstable angina: results of TIMA 11A. J Am Coll Cardiol. 1997; 29:1474-1482.
15. Hirsh J, Raschke B. Heparin and low molecular weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):188S-203S.
16. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447-452.
17. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
18. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L. Continuous intravenous heparin compared with subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med. 1986;315:1109-1114.
19. Schlitt A, Buerke M, Hauroeder B, Peetz D, Hundt F, Bickel C, Schaefer I, Meyer J, Rupprecht HJ. Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex-vivo rabbit model. Thromb Haemost. 2003;90:245-251.
20. Anticoagulation and enoxaparin use in patients with prosthetic heart valves and/or pregnancy. An evidence-based review and focused analysis of current controversies and clinical strategies. Clin Consensus Rep. 2002;1-18. Published by American Health Consultants, 3525 Piedmont Road, NE, Six Piedmont Center, Suite 400, Atlanta, GA 30305.
21. Salazar E, Izaguirre R, Verdejo J, Mutchinick O. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac prostheses. J Am Coll Cardiol. 1996;27:1698-1703.
22. Laurent P, Dussarat GV, Bonal J, Jego C, Talard P, Bouchiat C, Cellarier G. Low molecular weight heparin: a guide to their optimum use in pregnancy. Drugs. 2002;62:463-477.
23. Gohlke-Barwolf C. Anticoagulation in valvar heart disease: new aspects and management during non cardiac surgery. Heart. 2000;84: 567-572.
24. Goodney PP, Stukel TA, Lucas FL, Finlayson EV, Birkmeyer JD. Hospital volume, length of stay and readmission rates in high risk surgery. Ann Surg. 2003;238:161-167.